Cost-effectiveness of Erythropoietin for Chemotherapy-Induced Anaemia
Author Information
Author(s): G Barosi, M Marchetti, NL Liberato
Primary Institution: IRCCS Policlinico S. Matteo, Pavia, Italy
Hypothesis
Is recombinant human erythropoietin (rHuEPO) cost-effective compared to conventional treatment for chemotherapy-induced anaemia?
Conclusion
Recombinant human erythropoietin is not cost-effective for treating chemotherapy-induced anaemia under current usage patterns.
Supporting Evidence
- rHuEPO increased quality-adjusted life expectancy by 8.4 days.
- The incremental cost-effectiveness of rHuEPO was $189,652 per QALY.
- Transfusion therapy alone remained the most cost-effective strategy.
- Even with favorable assumptions, rHuEPO's cost-effectiveness remained high.
- At current prices, rHuEPO is not cost-effective for chemotherapy-induced anaemia.
Takeaway
This study looked at whether a drug called erythropoietin, which helps with anaemia during cancer treatment, is worth the money compared to just using blood transfusions. It found that using the drug costs too much for the benefits it provides.
Methodology
Decision analysis comparing rHuEPO with RBC transfusions alone.
Potential Biases
Potential bias in favor of rHuEPO due to assumptions made in the analysis.
Limitations
The analysis is based on a hypothetical patient model and may not reflect real-world variability.
Participant Demographics
Mean age of 65 years, patients with severe anaemia due to chemotherapy.
Want to read the original?
Access the complete publication on the publisher's website